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A B S T R A C T
We have previously shown that the heterodimeric cytokine interleukin-12, and the homodimer of its larger
subunit p40, both bind to heparin and heparan sulfate with relatively high aﬃnity. In the present study we
characterised these interactions using a series of chemically modiﬁed heparins as competitive inhibitors. Human
interleukin-12 and p40 homodimer show indistinguishable binding proﬁles with a panel of heparin derivatives,
but that of murine interleukin-12 is distinct. Heparin markedly protects the human and murine p40 subunits, but
not the p35 subunits, from cleavage by the bacterial endoprotease LysC, further implicating the larger subunit as
the location of the heparin binding site. Moreover the essential role of the carboxyterminal D3 domain in heparin
binding is established by the failure of a truncated construct of the p40 subunit lacking this domain to bind.
Predictive docking calculations indicate that a cluster of basic residues at the tip of the exposed C′D′ loop within
D3 is important in heparin binding. However since the human and murine C′D′ loops diﬀer considerably in
length, the mode and three dimensional orientation of heparin binding are likely to diﬀer substantially between
the human and murine p40s. Thus overall the binding of IL-12 via its p40 subunit to heparin-related poly-
saccharides of the extracellular matrix appears to be functionally important since it has been conserved across
mammalian species despite this structural divergence.
1. Introduction
Interleukin 12 (IL-12) plays a key role in establishing cell-mediated,
TH1-type, immune responses by stimulating NK and T lymphocytes to
secrete γ-IFN (for reviews see [1,2]). The major cellular sources of IL-12
are activated macrophages, monocytes and neutrophils. In turn, γ-IFN
stimulates further production of IL-12, thus giving rise to a positive
feedback loop at the initiation of TH1 responses. IL-12 is a relatively
large cytokine, Mr 70kD, being a heterodimer of two disulphide-bridged
subunits, p40 and p35. The p40 subunit also occurs as a component of
IL-23, in which the smaller p35 subunit is replaced by a structurally
related subunit, p19 [2]. IL-23 is a pro-inﬂammatory and im-
munostimulatory cytokine expressed by antigen presenting cells upon
activation. However IL-23 stimulates the TH17 lymphocyte subset,
thereby promoting both early responses to microbial infection and
chronic autoimmune states. The p35 subunit is also found in IL-35, an
immunosuppressive cytokine [3]. The high aﬃnity cell surface signal-
ling receptor for IL-12 is a heterodimer of the IL-12Rβ1 polypeptide,
which is also a component of the IL-23 receptor, and IL-12Rβ2, which is
shared with the IL-35 receptor [3]. Free p40 is also found in serum in a
number of disease states and in eﬀorts to identify the biological role of
this polypeptide a number of binding proteins have been identiﬁed,
including the CD5 glycoprotein [4].
The pivotal role of IL-12 in initiating and promoting TH1 immune
responses was convincingly demonstrated in IL-12 p40 deﬁcient mice,
which show greatly impaired γ-IFN responses to antigenic challenge
[5], and are unable to mount an eﬀective TH1 response to Myco-
bacterium tuberculosis infection [6]. Moreover both p40−/− and p35−/−
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mice, despite having an otherwise resistant genetic background, show
susceptibility to Leishmania major infection and polarised TH2 immune
responses [7]. In humans, deﬁciencies in IL-12 production and signal-
ling have been found to cause susceptibility to disseminated Salmonella
and mycobacterial infections, including tuberculosis [8,9]. Based on
previous evidence from experimental rodent models of disease, IL-12
and p40 have become targets of interest in a number of chronic human
diseases with autoimmune and inﬂammatory aspects, including psor-
iasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, rheumatoid
arthritis and multiple sclerosis [reviewed in 10]. Ustekinumab, a hu-
manised p40-speciﬁc monoclonal antibody which blocks IL-12 and IL-
23 signalling [11], is now an approved therapeutic agent for psoriasis
and psoriatic arthritis [12,13], and also for the treatment of moderate
to severe Crohn’s disease in patients refractory to anti-TNF treatment
[14]. In addition IL-12 has long been recognised to have anti-tumour
activities [15], and the localised delivery of IL-12 remains under in-
vestigation in the experimental immunotherapy of cancer [16–18].
The p35 subunit of IL-12 shares weak sequence homology with IL-6,
a 4 α-helix bundle cytokine [19]. Likewise an extensive if weak se-
quence homology has been noted between p40 and the IL-6 receptor
polypeptide [20]. IL-12 can therefore be conceptualised as a 4-α helix
bundle cytokine covalently pre-bound to a soluble class I cytokine re-
ceptor chain. The high resolution crystallographic structures of human
IL-12 accord entirely with this paradigm [21,22]. The p35 subunit in-
deed has a 4 α-helix conformation, whereas p40 has 3 distinct ﬁ-
bronectin-like Ig domains. The p35 subunit docks into a hinge region
between the central p40 domain, D2, and the carboxyterminal p40
domain, D3. The epitope for ustekinumab lies within the aminoterminal
domain of p40, D1 [22]. Recent structural studies of IL-23 show that
briakinumab, another IL-12 and IL-23 blocking monoclonal antibody,
binds to p40 at the same site [23].
We have previously reported that human and murine IL-12 bind
with comparatively high aﬃnity to the sulfated glycosaminoglycans
(GAGs) heparin and heparan sulfate, HS [24]. This binding appears to
involve highly sulfated motifs within the GAG chains. Since several 4 α-
helix cytokines including ILs-2 [25], -4 [26], -5 [27], -6 [28], and -7
[29], are heparin-binding cytokines, it might be surmised that IL-12
binds to sulfated GAGs via p35. However our ﬁnding that the human
p40 dimer binds to heparin and HS in a manner indistinguishable from
human IL-12 indicates instead that the binding site resides within p40
[24].
The binding of a cytokine to heparin-related polysaccharides of the
extracellular matrix and cell surface will serve to retain the cytokine
close to its site of secretion within tissue microcompartments [30].
Given the biological role of IL-12 as an activating signal for T and NK
lymphocytes secreted by antigen presenting cells, the localised delivery
of IL-12 is likely to be physiologically signiﬁcant in the context of the
immunological synapse which forms as a tight physical contact between
antigen presenting cells and T cells. Interestingly γ-IFN, which is pro-
duced in response to IL-12, is also a heparin/HS binding cytokine [31],
suggesting that these GAGs are important in localising the initiation of
TH1 immune responses.
As has been well studied in the case of FGFs, heparin/HS may also
function as cytokine co-receptors, by participating in the formation of
cytokine-receptor complexes and thereby promoting signalling activity
[reviewed in 32]. Whether sulphated GAGs function as co-receptors for
IL-12 remains unclear, although we have shown that stripping the
murine natural killer cell line KY-1 of the GAG chondroitin sulfate B,
greatly reduces responsiveness to IL-12 in terms of interferon-γ secre-
tion, and that chondroitin sulfate B competes for the heparin binding
site on IL-12, albeit with lower aﬃnity [33].
Here we investigate further the structural basis of the interaction
between IL-12 and sulphated GAGs. We report experimental ﬁndings
which clearly implicate the carboxyterminal domain, D3, of the p40
subunit as the site of heparin binding. We have also employed theore-
tical docking calculations which predict that key amino acid residues
involved in heparin binding are located in basically charged clusters on
ﬂexible, exposed polypeptide loops near the carboxyterminus of p40
D3, a region of appreciable structural divergence between murine and
human IL-12.
2. Materials and methods
2.1. Materials
Recombinant murine and human IL-12s (rmIL-12 and rhIL-12), rhIL-
12 p40, and goat polyclonal anti-rmIL-12 and anti-rhIL-12 were pur-
chased from R&D Systems Europe Ltd. (Abingdon, Oxon, UK). Alkaline
phosphatase- and horseradish peroxidase-coupled anti-goat Ig, en-
doproteinase LysC (EC 3.4.21.50) and p-nitrophenyl phosphate tablets
were all obtained from the Sigma Chemical Co., St. Louis, MO, USA. A
series of chemically modiﬁed heparins, were prepared and structurally
characterised as fully described elsewhere [34]. PCR primers were
obtained from MWG Biotech (Edersberg, Germany). Murine IL-12 p35
and p40 cDNA clones in pBluescript were obtained from the American
Type Culture Collection (ATCC, Manassas, VA, USA). Restriction en-
donucleases were purchased from Promega Corporation (Madison, WI,
USA).
2.2. Heparin binding ELISA, proteolytic digestion and Western blotting
The binding of rIL-12 and its derivatives to an immobilised heparin-
BSA complex was studied by ELISA as described previously [24,25]. For
digestion with endoproteinase LysC, rIL-12 and p40 (1.25 μg/ml) were
incubated with 2 μg/ml enzyme in 20mM Tris–HCl buﬀer, pH8.0, at
37 °C. Aliquots, 20 μl, were removed at diﬀerent digestion times and
immediately boiled in SDS sample buﬀer. Digested samples were se-
parated by SDS PAGE on 15% (wt/vol) polyacrylamide gels and elec-
troblotted on to nitrocellulose. All other samples for Western blotting
were separated on 12% (wt/vol) gels. After blocking in PBS containing
5% (wt/vol) fat-depleted dried skimmed milk powder and 0.05% (vol/
vol) Tween for 30min, followed by washing in PBS, the blot was in-
cubated overnight at 4 °C in blocking buﬀer containing goat anti-IL-12
antibody at 1/2000 dilution. After washing in blocking buﬀer, the blot
was incubated with peroxidase-coupled anti-goat Ig diluted 1/2000 for
45min. Finally IL-12 immunoreactivity was detected by chemilumi-
nescence reagents (SuperSignal West Pico, Perbio, Tattenhall, Cheshire,
UK).
2.3. Murine IL-12 gene constructs and site directed mutagenesis
Murine p35 and p40 cDNAs were cloned directly into the pTriEx
vector (Novagen, Darmstadt, Germany) for expression in mammalian
cells. Following the approach of Lieschke et al. [35], a single chain
construct, psc70, was generated by splicing the sequence for p40 at its
carboxyterminus via a ﬂexible linker, (Gly4Ser)3, to codon 23 of the p35
cDNA, which encodes Arg, the ﬁrst residue following the presumptive
signal sequence. Within the p40 cDNA, an Nco1 restriction site was
introduced at the aminoterminal end by a single base change in the
second codon (TGT to GGT), and the stop codon was deleted at the 3′
extremity. These changes were introduced by PCR ampliﬁcation using
the following primers: p40-Nco1 (sense), 5′-CAAAGCACCTAGGGTCCT
CAGAAG-3′; p40-Nco1 (antisense), 5′-TTTAAAGGATCCACCACCGCCC
GAGCCACCGCCACCGGATCGGACCCT-3′; p35-linker (sense), 5′-AAAT
TTGGATCCGGTGGCGCCGGATCTAGGGTCATTCCAGTCTCTGGA-3′;
p35-C terminus (antisense) 5′-AAAAGCTGGAGCTCCACCGCG-3′, with
the Nco1 restriction sites shown underlined. P40 and p35 PCR products
were respectively digested with Nco1/BamH1 and BamH1/Not1 en-
zymes, puriﬁed electrophoretically, ligated and subcloned into the
pGEM-T Easy vector (Promega, Southampton, Hants., UK).
In order to produce the p40 variant, p40ΔD3, which lacks the D3
domain, a stop codon was introduced at the end of the D2 codon by PCR
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using the QuickChange site-directed mutagenesis kit (Stratagene
Europe, Amsterdam, Netherlands). The mutagenesis primers used for
this were; sense, 5′-CTTCATCAGGGACATCATCTAACCAGACCCGCCCA
AGAAC-3′ , and, antisense, 5′ – GTTCTTGGGCGGGTCTGGTTAGATGA
TGTCCCTGATGAAG-3′, with the nucleotide substitution underlined.
Parental strands were then digested with Dpn1 and PCR products were
transformed into XL-1B (Stratagene). All coding sequence constructs
were conﬁrmed by commercial DNA sequencing (MWG Biotech, Milton
Keynes, UK) using universal and internal primers.
2.4. Expression of recombinant IL-12 constructs
African green monkey kidney COS-7 cells were grown in DMEM
supplemented with 10% (vol/vol) FCS, 2mM glutamine and 100 μg/ml
gentamycin. Cells were transfected at 70–80% conﬂuence with 2 μg
plasmid DNA using GeneJuice transfection reagent (Novagen,
Nottingham, UK) following the supplier’s instructions. 18hrs after
transfection, the culture medium was replaced with a serum-free var-
iant. After a further 18hrs, conditioned medium, or cells extracted in
PBS containing 1% (vol/vol) NP40 and protease inhibitor set (Roche
Applied Science, Lewes, East Sussex, UK), were immediately denatured
by boiling in SDS sample buﬀer containing 5% (vol/vol) 2-mercap-
toethanol analysed by Western blotting as described above. The IL-12
bioactivity of conditioned supernatants from transfected cell cultures
was assayed according to their ability to induce γ-IFN expression in the
murine KY-1 natural killer cell line [36] as described fully elsewhere
[33].
2.5. Molecular modelling of human and murine IL-12 and predictive
docking with heparin oligosaccharides
Visualisation of the molecular models used the programs Insight and
Discovery Studio Visualiser (Accelrys, Cambridge, UK). Molecular sur-
faces coloured by interpolated charge were generated in Discovery
Studio Visualiser. Complete sequences of human and murine IL-12, and
their constituent sub-units, were modelled on the basis of crystal
structures; a description of the homology modelling protocols and
strategy is presented in the Supplementary Material. Sequence align-
ments for the p40 subunits are shown in Fig. S1, together with the
extent of the residues resolved within each of the crystal structures.
Docking calculations of heparin model ligands to protein structures
1F42 (human p40) and 1F45 (human p40 and p35 heterodimer) [21]
were performed as previously described, using the program Autodock
version 2.4 [37], in the virtual space of a cube of side 80 Å. This pro-
gram allows limited ﬂexibility in the ligand structure, but uses a rigid
body protein approximation. As this protocol limits the size of protein
model which can be used, subunits of the IL-12 protein models were
used for docking calculations, and for both human and mouse models,
the p40 subunit was split into D1 (N-terminal), and a two-domain D2-
D3 model. A p35-D2-D3 model was also investigated. Two heparin
pentasaccharide model ligands consisted of three GlcN2S6S residues
separated by IdoA2S residues, with the IdoA2S residues in the 1C4 and
2S0 ring forms respectively; an endecasaccharide model consisted of six
GlcN2S6S separated by IdoA2S residues. These model ligands have
ﬁxed glycosidic torsion angles taken from the PDB ﬁle 1HPN, a solution
NMR structure [38]. Flexibility was allowed for all exocyclic torsion
angles in the pentasaccharide models, but was not allowed for the en-
decasaccharide model. Partial atomic charges were obtained by ab initio
quantum chemistry calculations on 1-OMe 4-OMe substituted mono-
saccharides, in the Jaguar program (Schrodinger Inc, Portland, Oregon,
USA). Intermolecular interaction energies calculated in Autodock for
the heparin/IL-12 complexes were used to rank calculated complexes.
Docking calculations for IL-12 based on the crystal structure 3HMX, and
p40 models based on the structures 4EO8 and 3DUH were also carried
out using the ClusPro server v. 2.0, (http://cluspro.bu.edu/) [39], with
the tetrasaccharide heparin ligand option oﬀered by the server.
Fig. 1. Heparin-related glycosaminoglycans as competitors of the binding of IL-
12 to immobilised heparin. Competitive ELISA of the binding to immobilised
heparin BSA complex of (A) human recombinant IL-12, (B) human recombinant
p40, (C) murine recombinant IL-12. Throughout, 8 ng/well recombinant cyto-
kine was preincubated prior to addition to the ELISA plate wells, in the absence
(None) or presence of 50 μg/ml heparin-related glycosaminoglycan as follows:
intact bovine lung heparin (Hep), bovine heparan sulfate (HS), N-desulfated
heparin (NdeS), N-sulfated re-N-acetylated heparin (Nac), selectively 6-O-de-
sulfated heparin (6OdeS), or selectively 2-O-desulfated heparin (2OdeS). Solid
columns indicate binding to heparin-BSA coated wells, and open columns re-
present binding to wells coated with mock-conjugated BSA. Each column re-
presents means of triplicate wells, and error bars show ± standard error of the
mean.
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3. Results
3.1. Speciﬁcity of heparin binding
We sought to characterise the interaction between rIL-12 and he-
parin/HS using a series of chemically modiﬁed heparin preparations in
which speciﬁc sulfate moieties had been removed. We examined the
eﬀects of these preparations on the binding of rhIL-12 to an im-
mobilised synthetic heparin-BSA complex using an ELISA method as
previously described [25]. As shown in Fig. 1 panel A, and entirely
consistent with our previously published ﬁndings [24], rhIL-12 binds
strongly to wells coated with this complex, whereas wells coated in-
stead with mock-conjugated BSA show only minimal binding. Pre-
incubation for 15min of rhIL-12 with soluble heparin and HS reduces
binding to the complex to the low background levels which occur in
control wells coated with mock-conjugated BSA. Thus this shows
complete competition for the speciﬁc binding to immobilised heparin.
However at the same concentration, 50 μg/ml, soluble chemically
modiﬁed heparins provide only partial inhibitions. Over a series of
three independent experiments, the selectively N-desulfated, N-desul-
fated/N-reacetylated, and 6-O-desulfated preparations were found to
give average inhibitions of 65, 70 and 56% respectively. The same
experiment conducted instead with the rhIL-12 p40 homodimer, Fig. 1
panel B, yields essentially indistinguishable results. However, when
rmIL-12 was investigated (Fig. 1 panel C), the N-desulfated preparation
is substantially less potent than the other preparations, including the N-
desulfated/N-acetylated and 6-O-sulphated derivatives, giving only
some 20% inhibition of binding. This indicates a species diﬀerence in
the speciﬁcity of the IL-12 heparin binding interactions.
3.2. Protection from proteolysis
We next investigated the eﬀect of heparin on the digestion of the
subunits of IL-12 with the endoproteinase Lys-C. This enzyme cleaves
polypeptide chains at lysine, which by possessing a basically charged
sidechain is, along with arginine, a key residue in the binding sites for
the acidic GAGs. The digestion products were examined by im-
munoblotting. As may be seen in Fig. 2 panel A, the undigested human
rhIL-12, TO material, (top left) shows two strong immunoreactive bands
of apparent Mrs 45 and 35kD, corresponding respectively to the p40
and p35 subunits of IL-12. Under the conditions employed, the p35
band proves to be highly susceptible to digestion, as in the absence of
heparin the immunoreactive band has completely disappeared by
60min, and is already considerably diminished by 15min. The high
resolution structures of IL-12 [21,22] reveal that a number of the lysine
residues in p35 are highly exposed within the cytokine structure. The
presence of heparin provides only minor protection as seen by reduced
degradation at 15min, however by 60min degradation appears almost
complete.
The human IL-12 45kD band is more resistant to digestion as in the
absence of heparin, 45kD immunoreactivity is seen throughout the di-
gestion period, although there is a progressive downward shift of the
major intensity to a position between the original p40 and p35 bands.
This indicates that a major immunoreactive intermediate on the de-
gradation pathway of p40 is a slightly smaller polypeptide suggesting
that sites susceptible to Lys C must be located relatively close to one or
both ends of the p40 polypeptide chain. Heparin results in more pro-
nounced protection of the human p40 subunit than that seen with p35.
After 120min digestion in the presence of heparin the major intensity at
45kD still migrates at an unchanged position, in complete contrast to
the near total loss of this band seen in the absence of heparin. Although
the more rapidly migrating band begins to appear in the presence of
heparin at later digestion times, it remains only a minor constituent of
the total immunoreactivity.
As shown in Fig. 2 panel B, similar Lys C digestion of the re-
combinant human p40 homodimer in the absence of heparin,
demonstrated that by 30min virtually all of the p40 immunoreactivity
has been shifted to a faster migrating position corresponding to the
clipped product discussed above for Fig. 2 panel A. By contrast, in the
presence of heparin the intact p40 immunoreactivity remains un-
diminished throughout the digestion period, and there is no evidence of
the lower Mr degradation intermediate under the conditions employed.
On the similar digestion of murine rIL-12 (Fig. 2 panel C), in the
absence of heparin, within 30min all the p40 immunoreactivity is faster
migrating, with two major bands discernible. One of these shows a
slight shift in migration, whereas the second migrates substantially
faster. This suggests two stages of clipping relatively near the ends of
the polypeptide. By 60min, the faster band predominates, and by
120min, it is the only remaining band albeit at very low intensity. As
with the human IL-12, heparin exhibits a clear protective eﬀect on
murine p40, since in its presence at 60min, the original p40 band is
essentially unchanged in migration or intensity. Moreover in the pre-
sence of heparin at no stage do either of the two major p40 degradation
bands appear. The murine p35, like its human counterpart, is more
rapidly degraded than the larger subunit, and similarly shows only
modest protection by heparin. Overall these observations show that for
both murine and human IL-12, heparin protects primarily the p40
subunit, at sites adjacent to the termini of the polypeptide.
We conducted in parallel, similar incubations of Lys-C with rhIL-10
in the presence and absence of heparin. In this case heparin failed to
protect the cytokine, indeed degradation of IL-10 appeared faster in the
presence of heparin (data not shown). These digestions establish that
the eﬀects observed with IL-12 are the speciﬁc outcomes of interactions
of heparin with this particular cytokine.
3.3. Recombinant IL-12 constructs
In order to locate the heparin binding site within murine IL-12, we
expressed recombinant constructs encoding the individual murine IL-12
subunits, and also a single chain variant of IL-12, psc70, in which the
subunits are fused using a ﬂexible linker. The latter has previously been
shown to possess high in vivo bioactivity [35]. We also expressed a
truncated variant of p40, p40ΔD3, in which the D3 domain is deleted.
These constructs are represented schematically in Fig. 3A. As shown in
Fig. 3B, in the conditioned supernatants harvested from transfected
cells strong immunoreactive bands were detectable by Western blotting
at the predicted Mrs for psc70 (lane 2) and p40 (lane 3), with the latter
resolving as a doublet. However in the case of attempted p35 expression
(lane 4), there is no clear band of around 35kD co-migrating with the
lower band detected in commercial rmIL-12 (lane 5). This may be in
part because the expression and secretion of p35 occurs less eﬃciently
compared to the p40 subunit [40], but also because the p35 subunit is
less immunogenic, and therefore less readily detectable by im-
munological techniques [41]. The weak detection of p35 compared to
p40 is indeed seen with the commercial rmIL-12 in lane 5. For the
p40ΔD3 construct (lane 1), a strong immunoreactive band migrates
with an apparent Mr of approximately 35kD, consistent with the pre-
dicted size. The conditioned supernatant from COS cells transfected to
express psc70 was found to have high IL-12 bioactivity as determined
by the induction of γ-IFN secretion in a natural killer cell line [36]. No
such bioactivity could be detected in the supernatants of COS cells ei-
ther mock transfected, or transfected to express the p40 polypeptide
(data not shown), ﬁndings entirely consistent with previous studies
[1,35].
The conditioned supernatants from the transfected COS cells were
analysed by heparin binding ELISA. In these ELISAs, sample volumes
were routinely adjusted to provide comparable loadings as judged by
band intensities in Western blotting. As may be seen in Fig. 3C, strong
heparin-binding IL-12 immunoreactivity was detectable in the condi-
tioned supernatant from psc70 transfected COS cells. This binding im-
munoreactivity was completely displaced in the presence of a low
concentration of soluble heparin. Thus the psc70 immunoreactivity
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behaved in an identical manner to commercial, puriﬁed rmIL-12 as
observed elsewhere in this study (Fig. 1C), and previously [24]. The
conditioned supernatant from p40-transfected cells provided compar-
ably strong heparin-binding IL-12 immunoreactivity which was also
completely displaced by soluble heparin, again consistent with our
previous results for commercial puriﬁed recombinant human p40
(Fig. 1B and [24]). By contrast the p40ΔD3 supernatant failed to pro-
vide heparin-binding IL-12 immunoreactivity, despite the same sample
exhibiting strong IL-12 immunoreactivity on Western blotting (Fig. 3B).
Indeed, compared to the Western blotting experiment, the sample em-
ployed in Fig. 3C had been uploaded to maximise the prospect of de-
tecting any binding. Thus the failure of p40ΔD3 to bind in this ELISA
demonstrates that the D3 domain of p40 has a critical role in the he-
parin binding of IL-12.
3.4. Predictive docking of heparin oligosaccharides and IL-12
The predominant feature of a heparin binding site is a cluster of
positively charged arginines and/or lysines, available for ionic inter-
actions with sulfate and carboxyl groups of the highly anionic GAG
chains [30]. As displayed in supplementary Fig. 1, the sequence of
human p40 shows a single prominent cluster of 6 these basic residues
within the 9 sequence positions 279–287 inclusive. We had proposed
solely on the basis of sequence that the cluster of basic residues here
was likely to constitute a heparin binding site [24]. Fig. S1 also shows
that murine p40 possesses 8 basic residues in a longer but corre-
sponding sequence, 269–282.
In order to evaluate these basic residue clusters, together with other
surface regions of p35 and p40, as possible locations of the heparin-
binding sites on IL-12, we used systematic docking calculations that
searched the entire protein surface, using heparin oligosaccharide
model probes. We generated protein structures for human and murine
IL-12 and their subunits using homology modelling as described in the
Supplementary Material. A complete molecular model of human IL-12,
with all loops completed by homology modelling, is shown in Fig. 4A.
As shown by electrostatic surface maps, Fig. 4B–E, domain D1 of p40
has few basic surface residues in both the human and murine poly-
peptides (there being 81% identity between these two sequences). By
contrast, as may be seen in Fig. 4B and C, in both species the surface of
D3 has a large electropositive patch due to the basic sequences referred
to above. On the reverse faces (Fig. 4D and E) there are fewer basic
amino acids and these are dispersed amongst acidic and neutral re-
sidues.
Docking calculations using Clus-Pro 2.0 and the 3HMX model of
whole human IL-12 identiﬁed the electropositive patch in the D3 do-
main as the main feature of the heparin binding site (Fig. 5A). More
detailed predictive docking calculations, using the programme Auto-
dock 2.4, were performed for interactions of murine and human IL-12
subunits with heparin oligosaccharide ligands. Our protocol for this
procedure has proved a reliable method for the identiﬁcation of heparin
Fig. 2. Digestion of IL-12 with Lys-C in the presence and absence of heparin. Human IL-12 (panel A), human p40 (panel B), and murine IL-12 (panel C) were each
digested with Lys-C at 37 °C in the presence (+) and absence (−) of 50 μg/ml heparin. The time in minutes of sampling after the start of digestion is shown above
each pair of tracks. Each panel is representative of triplicate experiments. Digestion products were separated by SDS PAGE on 15% (wt/vol) polyacrylamide gels and
immunoblotted with the appropriate polyclonal antibody. The migration of molecular weight markers are indicated in kD.
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binding sites on proteins, including those which, like IL-12, possess ﬁ-
bronectin-like domains [42]. Docking calculations did not identify any
heparin binding site on the D1 domain of the p40 subunit from either
species (data not shown). However, these calculations for both penta-
saccharide and endecasaccharide heparin oligomers with models of the
human IL12 p40 D2/D3 domains predicted the presence of a heparin-
binding site formed from the three loops at the distal end of subunit D3
in p40, corresponding again to the basic patch in domain D3 (Fig. 5B,
Fig. S2A). The human D3 domain is subject to C-α-mannosylation of
tryptophan residue W319 in both recombinant and endogenously ex-
pressed IL-12 [43]. The same modiﬁcation has been more recently
observed in p40 of IL-23 [44]. This mannosyl residue is not represented
in the available structures we have used in our modelling, but ex-
amination of the human p40 structure indicates that it is removed from
our proposed heparin binding site we and therefore unlikely to aﬀect
this interaction.
Calculations for murine p40 predicted a heparin-binding site similar
to that for the human protein (Fig. 5C). However, the more extended
282–292C′D′ loop at the distal end of D3 has a direct eﬀect on the
predicted heparin binding site in murine IL-12, both because of the
increased size of the loop, and because the introduced sequence in-
cludes an acidic cluster of three glutamate residues (E283, E285, E286),
which will engage in mutual charge repulsion with the highly acidic
heparin oligosaccharides. Thus the heparin complex with murine D2/
D3 (Fig. 5C) and with a D2/D3/p35 construct (Fig. S2B) shows heparin
interacting with a line of basic residues running from the loops at the
tip of D3 towards the interface with D2.
Docking calculations with the isolated human and mouse p35
subunits identiﬁed a potential heparin-binding site consisting of basic
residues along helix A (data not shown), close to the interface between
p35 and p40 subunits. As may be seen on the electrostatic potential-
coded surfaces shown in Fig. 4B and C for human and murine IL-12
respectively, both models have a distinct basic patch including one face
of D3, neighbouring basic residues in D2, and helix A of the p35 sub-
unit, and it is possible that both the D2 domain and the p35 subunit
contribute to binding of longer heparin polysaccharide molecules.
Interestingly, the docking calculations implicate the region of
lowest homology between the human and murine p40 subunit se-
quences, the C′D′ loop of D3, as an element of the IL-12 heparin binding
site. This loop shows the greatest variation between the species, with a
considerable number of amino acid substitutions, 8 inserted residues in
the mouse protein, and a diﬀerent charge proﬁle: the human sequence
being more uniformly basic than the mouse (see Figs. S1, Fig. 4B and
C). In addition this region is the least well deﬁned structural element in
the D3 domain, having a considerable degree of conformational
freedom (see Supplementary Material). This precludes a precise static
description of the heparin binding site from our docking calculations.
In summary, the predictive modelling results identify the D3 do-
main loops of the p40 subunit as the core heparin binding site for both
human and mouse IL-12. Docking calculations using two distinct al-
gorithms give results in close agreement. Calculations using longer
heparin oligosaccharides raise the possibility that the D2 domain or the
p35 subunit may contribute to an extended heparin binding site, par-
ticularly for mouse IL-12. All of the docking calculations identify non-
contiguous, conformationally formed heparin binding sites involving
several basic residues, and the inherent conformational ﬂexibility of the
Fig. 3. Heparin binding properties of recombinant
murine IL-12 constructs. (A) Schematic re-
presentation of the expressed constructs. The p40
polypeptide is represented as an open ribbon with
the three domains indicated. The p35 polypeptide
is represented as a ﬁlled ribbon. In the psc70
construct, the ﬂexible linker 15-mer peptide se-
quence used to fuse the subunit polypeptides is
represented by a shaded box marked L. (B)
Western blots of conditioned supernatants from
transfected COS cells. The individual tracks were
loaded with supernatants from cultures trans-
fected with (1) p40ΔD3, (2) psc70, (3) p40, and
(4) p35. Track (5) was loaded with commercially
expressed recombinant murine IL-12. Track (4) is
a maximal loading, whereas tracks (1)–(3) were
downloaded at least three fold to provide com-
parable densities on immunodevelopment with
each other and the p40 band of track (5). Samples
were separated on 12% polyacrylamide gels. The
migration of molecular weight markers are in-
dicated in kD. (C) Heparin-binding ELISA of IL-12
constructs. ELISA plate wells were coated with
synthetic heparin-BSA conjugate and used as a
capture surface for samples of condition super-
natants from transfected COS-7 cells which had
been preincubated in the absence (−) or presence
(+) of 5 μg/ml soluble heparin. Each column
shows the mean of quadruplicate wells and error
bars represent the standard error of the mean. The
loadings of the supernatants for psc70 and p40
were adjusted as for panel B, except that p40ΔD3
was uploaded 2-fold to maximise any possible
signal. The data shown are from a single experi-
ment, representative of a series of three.
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loop region does not encourage the suggestion of a single deﬁned pose
for bound heparin.
4. Discussion
We previously determined that the immunostimulatory cytokine IL-
12, both human and murine, binds to heparin and highly sulfated
variants of HS [24]. This has since been conﬁrmed independently by
studies elsewhere which employed isothermal titration calorimetry to
estimate the apparent dissociation constant for the binding of human
IL-12 to heparin as being around 70 µM [45]. In the present study we
examined further the heparin binding properties of human and murine
IL-12. Firstly, we employed a panel of chemically modiﬁed heparins to
investigate their heparin binding speciﬁcity proﬁles (Fig. 1). Each of the
chemically modiﬁed heparin preparations chosen lacks sulfate at one of
the three major sites of sulfation in the heparin disaccharide repeat
unit: 2-O-sulfate, the 6-O-sulfate, or the N-sulfate. As the modiﬁed he-
parins are all able to interact with both human and/or mouse IL-12 to
some extent, it can be concluded that none of the three positions of
Fig. 4. (A) A molecular model of the complete human IL-12 sequence based on
the crystal structure 3HMX. The model is displayed as a ribbon, coloured ac-
cording to secondary structure, with β-strands shown in aquamarine, and α-
helices in red. (B–E) Molecular surfaces of human (B and D) and mouse (C and
E) IL-12 coloured by interpolated charge (blue for basic, red for acidic). The D1
domains have a predominantly acidic surface, on which no heparin-binding site
could be deﬁned. Basic amino acid clusters are conﬁned principally to domain
D3, with contributions from D2 and from helix A of the p35 subunit. (D) and (E)
show the reverse faces from those in (B) and (C). (For interpretation of the
references to colour in this ﬁgure legend, the reader is referred to the web
version of this article.)
Fig. 5. Predicted complexes of heparin oligosaccharides with IL-12 sub-
structures. (A) The 3HMX model of whole human IL-12 docked with a heparin
tetrasaccharide using Clus-Pro 2.0. (B and C) Heparin pentasaccharide docked
with (B) human and (C) murine p40: in both cases only the D2 domains (left)
and D3 domains (right) are shown. Amino acid residues predicted to be in
contact with bound heparin are shown in green stick format and labelled. In all
panels, polypeptide β-strands are shown in aquamarine, and red represents α-
helices. The heparin oligosaccharides are shown in ball and stick representation
with oxygen atoms in red and sulphur atoms in yellow. Side-chains of predicted
heparin-binding basic residues are shown in green. In each panel the ten lowest
energy orientations are overlaid. (For interpretation of the references to colour
in this ﬁgure legend, the reader is referred to the web version of this article.)
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sulfation is absolutely required for binding to IL-12. Compared to other
heparin binding proteins we have studied using the same chemically
modiﬁed heparin preparations in this competitive ELISA approach,
human IL-12 shows a distinct binding proﬁle. For instance we estab-
lished that the N-desulfated heparin is a largely ineﬀective competitor
of the binding of the cytokine GDNF to immobilised heparin [34],
whereas here with human IL-12 it proves to be an eﬀective competitor
(Fig. 1A). With human IL-12, re-N-acetylation of this preparation has
little eﬀect in this competitive activity. The human p40 subunit
homodimer shows a very similar competitive binding proﬁle to that of
the human IL-12 heterodimer (Fig. 1B), indicating that the presence or
absence of the p35 subunits had little or no eﬀect on heparin binding.
This provides evidence that the heparin binding site of IL-12 resides
solely in the larger subunit. By contrast murine IL-12 shows a markedly
diﬀerent proﬁle (Fig. 1C), as in this instance N-desulfated heparin is a
relatively weak competitor which on re-N-acetylation becomes sig-
niﬁcantly more eﬀective. Thus these data reveal a species diﬀerence
between these two IL-12 heparin binding sites.
Next we investigated the ability of heparin to protect IL-12 from
controlled proteolysis by the endoprotease Lys C (Fig. 2). We previously
used this approach as part of establishing that the human cytokine
betacellulin binds to heparin and HS [46]. For such work the en-
doprotease LysC is the enzyme of choice because it cleaves adjacent to
lysine residues, which due to their strongly basic side chains and are
along with arginines, key residues in heparin binding sites. In con-
sidering the outcomes here, it must it must be borne in mind that he-
parin might bind to a site on a polypeptide without necessarily oﬀering
such protection, and also that upon immunoblotting of the digestion
products, only those fragments retaining major epitope(s) will be de-
tectable. However, overall these experiments indicate that the p35
subunit shows only limited protection (Fig. 2A and C), and the p40
subunit is the primary locus of heparin protection. This further suggests
that the p40 subunit is the location of the heparin binding site. A major
eﬀect of heparin on p40 digestion was that it prevented the appearance
of large polypeptide fragments of slightly increased electrophoretic
migration, indicating that one or more sites relatively near the p40
polypeptide chain terminii were being protected by heparin.
To further localise the heparin binding site of IL-12 we expressed a
series of murine IL-12 constructs. These were psc70, a bioactive single
chain construct encompassing both chains of the heterodimer [35], as
well as p35, p40 and p40Δ3. Conditioned supernatants of all of these
except p35 gave strong immunoreactive bands on immunoblotting,
with migrations corresponding to the anticipated molecular weights
(Fig. 3B). However despite the strong heparin-displaceable im-
munoreactivity demonstrated in the heparin binding ELISA for psc70
and intact p40, none was detectable for p40ΔD3 (Fig. 3C). Thus was
despite the use of an elevated loading of the latter supernatant. This
total loss of aﬃnity for heparin in the truncated construct demonstrates
that the heparin binding site resides in the carboxyterminal D3 domain
of p40.
The aminoacid sequence of p40 contains a prominent basic residue
cluster of 6 arginines and lysines in the case of the human protein, and 8
for the murine polypeptide. These lie in the C′D′ loop near the middle of
the D3 domain, a region of low sequence homology between the human
and murine proteins due to an 8 residue insertion in the mouse se-
quence. In both species this sequence cluster forms the core of a large
exposed electropositive patch on the concave face of the D3 domain.
Through the use of well-established molecular docking simulations we
show that binding of heparin oligosaccharides to these sites is entirely
feasible, although the detailed interactions diﬀer between the human
and murine IL-12s due to structure divergence in this region. In the
molecular structures available for the p40 subunit, the C′D′ loop, along
with the aminoterminal sequence, are the two largest unresolved por-
tions of the polypeptide. This implies conformational ﬂexibility of the
C’D’ loop in both species.
The heparin binding sites in human and murine p40s we presently
propose involve the prominent clusters of basic residues that, on the
basis of sequence alone, we had previously suggested might be im-
portant in this interaction [24]. More recently, Jayanthi et al [45] in-
dependently proposed two possible heparin binding sequences within
human p40, the longer of which is essentially the C′D′ loop of D3 and in
agreement with our proposal. Their shorter sequence, Leu117-Lys127,
is exposed on the surface of D2. Our present predictive modelling stu-
dies of heparin-human IL-12 interactions identify the former sequence,
with no involvement of the latter for the relatively short heparin oli-
gosaccharides modelled. By contrast, our modelling of the murine
binding site does show some involvement of this D2 sequence together
with other basic residues from a neighbouring β-strand.
In a number of studies the contribution of individual amino acid
residues within heparin binding sites has been probed by site-directed
mutagenesis, although precise delineation of the key residues involved
is often diﬃcult. Our recent mapping of the extended heparin binding
site on the BMP antagonist gremlin [47] has shown that the substitution
of as many as six basic residues was not able to abrogate heparin
binding completely. By contrast to gremlin, in which the conformation
of the polypeptide within the heparin binding site is constrained by
intra-chain disulphide bridges of the TGF-β fold, our predictions for IL-
12 implicate residues within the unordered and relatively un-
constrained loops joining the packed α-helices of D3. Because of the
probable conformational ﬂexibility of these loops it is likely that the
substitution of any residue within them, irrespective of sidechain
charge, will alter sidechain packing and therefore the conformation of
the loop within the mutant variant. Any such conformational change
might well aﬀect aﬃnity for heparin, even when if the targeted residue
has no direct interaction with the polysaccharide. Thus probing these
loops by mutagenesis is unlikely to reliably identify the key contact
residues.
The human p40 D3 domain contains tryptophan W319, which as
referred to above is the site of mannosylation. This residue also lies at
the start of WSXW motif, which in most thrombospondin repeat type 1
domains, and some ﬁbronectin type III domains, forms the base of a so-
called tryptophan ladder involving basic residues on neighbouring β-
strands (for review see Olsen and Kragelund [48]). There is some evi-
dence that one function of such ladders is to associate with anionic
components of the extracellular matrix, including heparin and related
polysaccharides. Within human D3, there is a truncated tryptophan
ladder involving only the tryptophan tetrapeptide motif and a single
basic residue R309, as shown in Fig. S4. Our unbiased binding protocols
found no potential interaction with this tryptophan step. In any case
there is no tryptophan step in murine p40.
A detailed structural elucidation of the interaction of IL-12 with its
high-aﬃnity receptor polypeptides β1 and β2 is not yet available.
However, Yoon et al. have proposed that the exposed face of p35 is
important in IL-12/IL-12 receptor interactions [21]. Moreover, the
binding site for the Mab ustekinumab, which neutralises IL-12 activity,
is located on the exposed long axis of the D1 domain of p40 [22], well
removed from the heparin binding sites we propose here. Even in the
hexameric IL-12/IL-12 receptor signalling complex postulated by Yoon
et al. [21], the heparin binding sites we propose remain exposed. Very
recently Bloch et al. [23] have produced a high resolution structure of
the related IL-23 complexed with the extracellular domain of IL-23R.
This shows that the major contact is between D1 of this receptor chain
and the peptide loops of an exposed end of p19, although there is also
minor contact with D1-D2 hinge region of p40, inducing a 5–10° ﬂexing
of the D1-D3 orientation. The surface of D3 remains exposed in this
complex.
This apparent separation between the likely receptor binding sites
and the heparin binding sites is consistent with our observations (data
unpublished) that addition of sulfated GAGs including heparin and HS
neither inhibits nor potentiates murine IL-12 bioactivity in the KY-1
cellular assay [33]. Subsequently, in studies of human IL-12 in human
natural killer cell line NK-92MI and with human peripheral blood
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mononuclear cells, heparin was found to potentiate IL-12 activity [49].
Although this apparent species diﬀerence may arise from variations
between the assay systems employed, it is also consistent with the
diﬀerence we propose between the heparin binding sites of murine and
human IL-12.
Irrespective of the eﬀect of heparin and HS on IL-12 activity, it is
likely that a major physiological eﬀect of this interaction is the te-
thering of the cytokine close to its sites of secretion within the tissues by
binding to HS chains of adjacent cell surfaces and extracellular matrix
[30]. Indeed Jayanthi et al. [49] have reported the binding of rhIL-12 to
cell surfaces which was markedly increased by the addition of soluble
heparin, which may be indicative of heparin/HS providing a reservoir
of IL-12 at the cell surface HS. This binding would function to localise
the immunoregulatory activity of IL-12. Such localised, paracrine ac-
tivity of IL-12 has been proposed to underlie the eﬀectiveness of IL-12
secreting chimeric antigen receptor (CAR)-modiﬁed T cells in elim-
inating experimentally induce tumours [50]. Since the cytokines IL-12
and γ-IFN constitute a positive feedback loop for the stimulation of TH1
immune responses, and the latter is also a heparin/HS binding cytokine
[31], this suggests an important role for HS in the paracrine stimulation
of cellular immune responses. As the p40 subunit is also a component of
the immunostimulatory cytokine IL-23, it is a reasonable speculation
that it too will be localised in this way.
In summary, it is clear that both murine and human IL-12 bind to
heparin and related polysaccharides via the carboxyterminal D3 do-
main of their p40 subunits. The conformational plasticity of the exposed
loops in this domain render precise delineation of the binding site im-
practical, but our molecular simulations predict the C′D′ loop of D3 as
being central to this interaction. This loop contains a prominent cluster
of exposed lysine residues and being near the C-terminus of the poly-
peptide chain, is consistent with the observed protection by heparin
from clipping with the endoprotease Lys-C. This loop is the region of
lowest homology between the two orthologs, showing diﬀerences in
sequence, length and charge. It would therefore appear that the re-
quirement to interact with the sulfated polysaccharide ligand has not
constrained the polypeptide from undergoing considerable evolu-
tionary divergence within this loop. Such divergence of the heparin
binding site of a protein between mammalian species is somewhat
unexpected. Indeed, in a comparative study of FGF-FGFR-heparin in-
teractions, in which the structure of human FGF1-FGFR2-heparin
complex was compared to models of the Drosophila melanogaster FGF-
FGFR2-heparin and Caenorhabditis elegans egl17-egl15-heparin com-
plexes, it was deduced that despite numerous amino acid substitutions
involving key residues, the heparin binding site was evolutionarily well
conserved in terms of the positioning of the bound heparin chain [51].
By contrast, within the BMP-2/BMP-4 subfamily of the bone morpho-
genetic proteins, these two cytokines bind heparin via aminoterminal
sequences which show both sequence divergence and conformational
ﬂexibility (for review see [52]). It is also notable in this context that
osteopontin is a heparin binding protein which is intrinsically un-
structured with considerable conformationally ﬂexibility in solution
[53]. Our present predictions with IL-12 add further insight into the
evolution of heparin-protein interactions. In this case we conclude that
as long as evolutionary changes do not actually abolish heparin
binding, considerable ﬂexibility in the structure of heparin binding sites
is permissible. This implies that the functional importance of heparin
binding does not necessarily depend on a precise orientation and
alignment of the bound polysaccharide chain with respect to the do-
mains of the polypeptide.
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